FluxMPS™ Leibovitz's L-15 Medium w/o L-Glutamine, Phenol Red: 1X Liquid

FluxMPS™ Leibovitz's L-15 Medium w/o L-Glutamine, Phenol Red: 1X Liquid

Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) 1X liquid Leibovitz's L-15 medium engineered for microfluidic channels, organ-on-a-chip (OoC), and microphysiological systems (MPS). This CO₂-independent, galactose-based formulation omits L-glutamine and phenol red for applications requiring reduced background or user-controlled glutamine supplementation. Manufactured under ISO 13485:2016 in an ISO Class 5 fill environment using Ultrapure Type 1 water (18.2 MΩ·cm). A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.

• Quadruple-stage filtration to a 0.04 µm final cut-off — mycoplasma-retentive prefiltration and sub-micron particulate reduction
• Endotoxin release specification: < 0.05 EU/mL (USP <85> BET, per-batch release)
• Galactose-based (0.9 g/L), glucose-free carbon source with 550 mg/L sodium pyruvate — CO₂-independent, phosphate-buffered, bicarbonate-free
• L-Glutamine and Phenol Red omitted for user-controlled supplementation and reduced optical background applications
• Ultrapure Type 1 water (18.2 MΩ·cm) — low trace-metal and organic-carbon background
• USP <788> Method 1 (light obscuration) particulate compliance — supports narrow microfluidic channel geometries
• ISO Class 5 (Class 100) laminar-flow aseptic fill & finish; manufactured under ISO 13485:2016
• Custom pH, carbon source, HEPES, salts & nutrients available on request — support@diagnocine.com

Engineered where standard media fails

Conventional 0.22 µm filtered media allows mycoplasma (0.2–0.3 µm), sub-visible particulates, and microaggregates to pass freely — clogging microchannels, corrupting biosensors, and invalidating metabolic assays. FluxMPS™ closes that gap.

Quadruple-stage filtration system

FluxMPS™ Leibovitz's L-15 Medium undergoes a validated four-stage sequential filtration process reaching a final pore size of 0.04 µm — two dedicated prefilter-plus-final-filter pairs run in series, engineered to reduce particulate and bioburden levels beyond conventional 0.22 µm-filtered media.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates, cell debris, and protein aggregates; protects the first 0.04 µm cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates that pass a 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm cartridge.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; aseptic fill in a validated ISO Class 5 (Class 100) laminar-flow workstation.

Optimized for next-generation cell biology platforms

FluxMPS™ Leibovitz's L-15 Medium w/o L-Glutamine, Phenol Red: 1X Liquid is validated for applications where microchannel cleanliness, signal fidelity, and metabolic precision are critical.

Automated Bioreactors & Robotics

For automated perfusion bioreactors and robotic liquid-handling systems, an optional 0.01 µm (10 nm) ultra nano-filtered MPS Grade variant of this formulation is available, adding 0.02 µm and 0.01 µm polishing stages after the standard 0.04 µm final filter.

• Total Particulate Exclusion — extended protection for microvalve and sensor surfaces
• Valve & Sensor Protection — reduced risk of fouling in long-running automated systems
• Extended Perfusion Stability — supports multi-week unattended perfusion protocols

Inquiry Required: The 0.01 µm MPS Grade variant is produced to order. Contact support@diagnocine.com to request this formulation.

Full technical specification

Every lot of FluxMPS™ Leibovitz's L-15 Medium w/o L-Glutamine, Phenol Red: 1X Liquid is released against comprehensive multi-parameter QC specifications.

Full composition (mg/L)

Every ingredient below is present in this 1X liquid formulation at the exact concentration listed. Total: 33 components across 4 categories. All values are per-lot verified and reported on the Certificate of Analysis (CoA).

Manufacturing & compliance

Every batch is subject to multi-parameter lot-release testing before distribution.

How DCP-LL15-QR1X compares

Advantages in filtration, mycoplasma barrier, water quality, and QC depth relevant to MPS and microfluidic applications.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ Leibovitz's L-15 Medium w/o L-Glutamine, Phenol Red: 1X Liquid (DCP-LL15-QR1X).

Supporting literature

1. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–1668. doi:10.1126/science.1188302
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. doi:10.1038/nbt.2989
3. Vander Heiden MG, et al. Understanding the Warburg effect. Science. 2009;324:1029–1033. doi:10.1126/science.1160809
4. Sontheimer-Phelps A, et al. Modelling cancer in microfluidic human organs-on-chips. Nat Rev Cancer. 2019;19:65–81. doi:10.1038/s41568-018-0104-6
5. van Duinen V, et al. Microfluidic 3D cell culture. Curr Opin Biotechnol. 2015;35:118–126. doi:10.1016/j.copbio.2015.05.002
6. Jang KJ, et al. Reproducing human drug toxicities using a Liver-Chip. Sci Transl Med. 2019;11:eaax5516. doi:10.1126/scitranslmed.aax5516
7. Kasendra M, et al. Primary human Small Intestine-on-a-Chip. Sci Rep. 2018;8:2871. doi:10.1038/s41598-018-21201-7
8. Skardal A, et al. Multi-tissue organ-on-a-chip platform. Sci Rep. 2017;7:8837. doi:10.1038/s41598-017-08879-x